Clinical Evaluation of the Adaptilens Accommodating IOL

Starting soon · Not applicable

Conditions studied: Aphakia Cataract

In brief

The goals of this feasibility study are to learn more about the performance of the intraocular lens (IOL), if the IOL is safe for use, and what the best surgical techniques are for implanting the IOL in patients who require correction of aphakia following phacoemulsification extraction of a senile cataract.

Key facts

Study ID

NCT07607860

Run by

Adaptilens, Inc.

People needed

100

Starts

2026-09-01

Expected to finish

2030-12-01

Last updated by the study team

2026-08-06

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults who are at least 21 years of age or older.
• Scheduled to undergo primary intraocular lens implantation for the correction of aphakia following phacoemulsification extraction of a senile cataract.
• Clear intraocular media other than cataract.
• Potential visual acuity of 20/32 or better in both eyes after cataract removal and IOL implantation as determined by diagnostic testing or investigator's judgement.
• Preoperative corrected distance visual acuity (CDVA) worse than 20/40 either with or without a glare source present (e.g., Brightness Acuity Tester) or scheduled for cataract removal due to significant cataract-related symptoms/complaints.
• Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism.
• In good general health at screening as determined by the investigator.
• Signed written informed consent.
• Availability, willingness, and sufficient cognitive awareness to comply with examination procedures and schedule.

You may not qualify if…

• Planned secondary procedures (such as LASIK) during the term of the study; Nd YAG capsulotomy is permitted.
• Taking systemic medications that may confound the outcome or increase the risk to the subject.
• Ocular conditions that may predispose for future complications.
• Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject.
• Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes.
• Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future CDVA loss worse than 20/40.
• Any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.).
• Glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP > 22 mmHg.
• Previous retinal detachment or retinal pathology, including age-related macular degeneration.
• Diabetes, currently being treated systemically and with retinopathy.
• Systemic or ocular disease that may prevent the patient from achieving CDVA of 20/32 or better post operatively.
• Require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents.
• CDVA of 20/32 or worse in the fellow eye not attributable to cataract.
• Current participation in, or have participated in, an investigational study, other than this study, within the previous 60 days before the operative day.
• Previous ocular surgery in the operative eye, including refractive surgery.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.